Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

14.3K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
14.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.2K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.7K
The pathophysiology of pneumonia involves the following steps:
3.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same author

Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study.

The Journal of infection·2026
Same author

Endocarditis Due to <i>Scedosporium</i> spp and <i>Lomentospora prolificans</i>: Case Series and Literature Review.

Open forum infectious diseases·2026
Same author

Clinical and epidemiological factors fail to predict NDM-5-producing Escherichia coli bloodstream infections among MBL-producing Enterobacterales.

International journal of antimicrobial agents·2026
Same author

Hematopoietic stem cell transplantation following invasive mold infection in chronic granulomatous disease: Insights from a case series and literature review.

Journal of human immunity·2026
Same author

Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections.

mBio·2026

Related Experiment Video

Updated: Mar 8, 2026

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
12:30

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection

Published on: November 22, 2013

41.6K

Legionnaire's Disease in Compromised Hosts.

Fanny Lanternier1, Florence Ader2, Benoit Pilmis1

  • 1AP-HP, Hôpital Necker-Enfants malades, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Université Paris Descartes, 149, rue de Sevres, Paris 75015, France.

Infectious Disease Clinics of North America
|February 5, 2017
PubMed
Summary
This summary is machine-generated.

Legionnaire's disease (LD) affects immunocompromised individuals, including those with cancer or organ transplants. This review covers immunity, diagnosis, and treatment for LD in these vulnerable patients.

Keywords:
LegionellosisTLR-5TNF blockersTNF-alphaTobacco

More Related Videos

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria
13:54

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria

Published on: April 2, 2013

11.0K
Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
08:34

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages

Published on: February 22, 2017

12.0K

Related Experiment Videos

Last Updated: Mar 8, 2026

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection
12:30

Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection

Published on: November 22, 2013

41.6K
Tractable Mammalian Cell Infections with Protozoan-primed Bacteria
13:54

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria

Published on: April 2, 2013

11.0K
Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages
08:34

Legionella pneumophila Outer Membrane Vesicles: Isolation and Analysis of Their Pro-inflammatory Potential on Macrophages

Published on: February 22, 2017

12.0K

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Legionnaire's disease (LD) is typically seen in immunocompetent individuals, with chronic lung disease and smoking as key risk factors.
  • However, LD also presents a significant risk for immunocompromised patients, notably those undergoing anti-tumor necrosis factor alpha therapy, with hematological malignancies, or post-transplantation.

Purpose of the Study:

  • To consolidate and discuss current data regarding Legionella spp. immunity.
  • To review the epidemiology, clinical presentation, diagnostic approaches, and treatment strategies for LD specifically in immunocompromised patient populations.

Main Methods:

  • Literature review of existing studies and clinical data.
  • Synthesis of information on Legionella immunity and LD in immunocompromised hosts.

Main Results:

  • Data indicates a notable incidence of LD in immunocompromised patients, highlighting specific risk groups.
  • Comprehensive understanding of immune responses to Legionella is crucial for managing LD in these patients.

Conclusions:

  • Legionnaire's disease poses a serious threat to immunocompromised individuals, requiring tailored diagnostic and therapeutic approaches.
  • Further research into Legionella immunity and optimal LD management in immunocompromised populations is warranted.